-
1
-
-
51249118258
-
Structural analysis of factor IX protein variants to predict functional aberration causing haemophilia B
-
Mukherjee S, Saha A, Biswas P, Mandal C, Ray K. Structural analysis of factor IX protein variants to predict functional aberration causing haemophilia B. Haemophilia. 2008;14:1076-81.
-
(2008)
Haemophilia
, vol.14
, pp. 1076-1081
-
-
Mukherjee, S.1
Saha, A.2
Biswas, P.3
Mandal, C.4
Ray, K.5
-
2
-
-
33645961280
-
Insight into molecular changes of the FIX protein in a series of Italian patients with haemophilia B
-
Bicocchi MP, Pasino M, Rosano C, Molinari AC, Della VE, Lanza T, et al. Insight into molecular changes of the FIX protein in a series of Italian patients with haemophilia B. Haemophilia. 2006;12:263-70.
-
(2006)
Haemophilia
, vol.12
, pp. 263-270
-
-
Bicocchi, M.P.1
Pasino, M.2
Rosano, C.3
Molinari, A.C.4
Della, V.E.5
Lanza, T.6
-
3
-
-
0031841277
-
Haemophilia B: Database of point mutations and short additions and deletions-eighth edition
-
Giannelli F, Green PM, Sommer SS, Poon M, Ludwig M, Schwaab R, et al. Haemophilia B: database of point mutations and short additions and deletions-eighth edition. Nucleic Acids Res. 1998;26:265-8.
-
(1998)
Nucleic Acids Res
, vol.26
, pp. 265-268
-
-
Giannelli, F.1
Green, P.M.2
Sommer, S.S.3
Poon, M.4
Ludwig, M.5
Schwaab, R.6
-
4
-
-
0027434188
-
Prospective study of the evaluation of hepatitis C virus infectivity in a high-purity, solvent/detergent-treated factor VIII concentrate: Parallel evaluation of other markers for lipidenveloped and non-lipid-enveloped viruses
-
The Ad Hoc Study Group of the Fondazione dell'Emofilia
-
Mariani G, Di Paolantonio T, Baklaya R, Morfini M, Mannucci PM. Prospective study of the evaluation of hepatitis C virus infectivity in a high-purity, solvent/detergent-treated factor VIII concentrate: parallel evaluation of other markers for lipidenveloped and non-lipid-enveloped viruses. The Ad Hoc Study Group of the Fondazione dell'Emofilia. Transfusion. 1993;33:814-8.
-
(1993)
Transfusion
, vol.33
, pp. 814-818
-
-
Mariani, G.1
Di Paolantonio, T.2
Baklaya, R.3
Morfini, M.4
Mannucci, P.M.5
-
5
-
-
0028136537
-
Review of the hepatitis A epidemics in hemophiliacs in Europe
-
Vermylen J, Peerlinck K. Review of the hepatitis A epidemics in hemophiliacs in Europe. Vox Sang. 1994;67(Suppl 4):8-11.
-
(1994)
Vox Sang
, vol.67
, Issue.SUPPL. 4
, pp. 8-11
-
-
Vermylen, J.1
Peerlinck, K.2
-
6
-
-
0023898771
-
Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrates
-
Bartolomei Corsi O, Azzi A, Morfini M, Fanci R, Rossi Ferrini P. Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrates. J Med Virol. 1988;25:165-70.
-
(1988)
J Med Virol
, vol.25
, pp. 165-170
-
-
Bartolomei, C.O.1
Azzi, A.2
Morfini, M.3
Fanci, R.4
Rossi, F.P.5
-
7
-
-
0029983755
-
Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate
-
Yee TT, Cohen BJ, Pasi KJ, Lee CA. Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate. Br J Haematol. 1996;93:457-9.
-
(1996)
Br J Haematol
, vol.93
, pp. 457-459
-
-
Yee, T.T.1
Cohen, B.J.2
Pasi, K.J.3
Lee, C.A.4
-
8
-
-
34248532042
-
Reformulated Bene FIX: Efficacy and safety in previously treated patients with moderately severe to severe haemophilia B
-
Lambert T, Recht M, Valentino LA, Powell JS, Udata C, Sullivan ST, et al. Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. Haemophilia. 2007;13:233-43.
-
(2007)
Haemophilia
, vol.13
, pp. 233-243
-
-
Lambert, T.1
Recht, M.2
Valentino, L.A.3
Powell, J.S.4
Udata, C.5
Sullivan, S.T.6
-
9
-
-
13244277651
-
Enhanced factor VIII activity measurements using ROTEG and factor VIII- mice whole blood
-
Landskroner KA, Olson NC, Jesmok GJ. Enhanced factor VIII activity measurements using ROTEG and factor VIII- mice whole blood. J Thromb Haemost. 2004;2:2274-5.
-
(2004)
J Thromb Haemost
, vol.2
, pp. 2274-2275
-
-
Landskroner, K.A.1
Olson, N.C.2
Jesmok, G.J.3
-
10
-
-
22744458031
-
Thromboelastography measurements of whole blood from factor VIII-deficient mice supplemented with rFVIII
-
Landskroner KA, Olson NC, Jesmok GJ. Thromboelastography measurements of whole blood from factor VIII-deficient mice supplemented with rFVIII. Haemophilia. 2005;11:346-52.
-
(2005)
Haemophilia
, vol.11
, pp. 346-352
-
-
Landskroner, K.A.1
Olson, N.C.2
Jesmok, G.J.3
-
12
-
-
84940137996
-
Biologic assay of a thrombosis- inducing activity in human serum
-
Wessler S, Reimer SM, Sheps MC. Biologic assay of a thrombosis- inducing activity in human serum. J Appl Physiol. 1959;14:943-6.
-
(1959)
J Appl Physiol
, vol.14
, pp. 943-946
-
-
Wessler, S.1
Reimer, S.M.2
Sheps, M.C.3
-
13
-
-
84892923759
-
A pharmacologic evaluation of BAY 79-4980 (liposomeformulated kogenate FS) in the hemophilia A mouse
-
Jesmok G, Cui ZH, Canivel D, Frounel M, Pierce G, Landskroner KA. A pharmacologic evaluation of BAY 79-4980 (liposomeformulated kogenate FS) in the hemophilia A mouse. Blood. 2006;11:108.
-
(2006)
Blood
, vol.11
, pp. 108
-
-
Jesmok, G.1
Cui, Z.H.2
Canivel, D.3
Frounel, M.4
Pierce, G.5
Landskroner, K.A.6
-
14
-
-
84892942889
-
Comparison of human rFVIII and murine rFVIII in a standardized FVIII dependent bleed model in FVIII - mice
-
Jesmok G, Cui ZH, Canivel D, Lollar P, Parker ET, Landskroner KA. Comparison of human rFVIII and murine rFVIII in a standardized FVIII dependent bleed model in FVIII - mice. J Thromb Haemost 2007;5 Suppl 2: 030.
-
(2007)
J Thromb Haemost
, vol.5
, Issue.SUPPL. 2
, pp. 030
-
-
Jesmok, G.1
Cui, Z.H.2
Canivel, D.3
Lollar, P.4
Parker, E.T.5
Landskroner, K.A.6
-
15
-
-
78650034120
-
Evaluation of PEG-FVIII molecules with prolonged half-lives in a murine FVIII-dependent bleeding model
-
Landskroner KA, Cui ZH, Newgren J, Fournel M, Pierce G, Jesmok G. Evaluation of PEG-FVIII molecules with prolonged half-lives in a murine FVIII-dependent bleeding model. Blood. 2006;11:108.
-
(2006)
Blood
, vol.11
, pp. 108
-
-
Landskroner, K.A.1
Cui, Z.H.2
Newgren, J.3
Fournel, M.4
Pierce, G.5
Jesmok, G.6
-
16
-
-
10144234803
-
Recombinant human factor IX: Replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B
-
Brinkhous KM, Sigman JL, Read MS, Stewart PF, McCarthy KP, Timony GA, et al. Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B. Blood. 1996;88:2603-10.
-
(1996)
Blood
, vol.88
, pp. 2603-2610
-
-
Brinkhous, K.M.1
Sigman, J.L.2
Read, M.S.3
Stewart, P.F.4
McCarthy, K.P.5
Timony, G.A.6
-
17
-
-
84890859035
-
Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: A prospective, controlled, multicenter phase I/III study in previously treated patients with severe (FIX level\1 %) or moderately severe (FIX Level B 2%) haemophilia B
-
Epub ahead of print
-
Windyga J, Lissitchkov T, Stasyshyn O, Mamonov V. Rusen L, Lamas JL et al. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: A prospective, controlled, multicenter phase I/III study in previously treated patients with severe (FIX level\1 %) or moderately severe (FIX Level B 2%) haemophilia B. Haemophilia. 2013 [Epub ahead of print].
-
(2013)
Haemophilia
-
-
Windyga, J.1
Lissitchkov, T.2
Stasyshyn, O.3
Mamonov, V.R.L.4
Lamas, J.L.5
-
18
-
-
0028958843
-
Measurement of activated factor IX in factor IX concentrates: Correlation with in vivo thrombogenicity
-
Gray E, Tubbs J, Thomas S, Oates A, Boisclair M, Kemball-Cook G, et al. Measurement of activated factor IX in factor IX concentrates: correlation with in vivo thrombogenicity. Thromb Haemost. 1995;73:675-9.
-
(1995)
Thromb Haemost
, vol.73
, pp. 675-679
-
-
Gray, E.1
Tubbs, J.2
Thomas, S.3
Oates, A.4
Boisclair, M.5
Kemball-Cook, G.6
-
19
-
-
33646262886
-
Overview of inhibitors
-
Astermark J. Overview of inhibitors. Semin Hematol. 2006;43:3-7.
-
(2006)
Semin Hematol
, vol.43
, pp. 3-7
-
-
Astermark, J.1
-
20
-
-
0038779279
-
Prophylaxis in factor IX deficiency product and patient variation
-
Kisker CT, Eisberg A, Schwartz B. Prophylaxis in factor IX deficiency product and patient variation. Haemophilia. 2003;9:279-84.
-
(2003)
Haemophilia
, vol.9
, pp. 279-284
-
-
Kisker, C.T.1
Eisberg, A.2
Schwartz, B.3
-
21
-
-
19944429262
-
The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B
-
Shapiro AD, Di Paola J, Cohen A, Pasi KJ, Heisel MA, Blanchette VS, et al. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood. 2005;105:518-25.
-
(2005)
Blood
, vol.105
, pp. 518-525
-
-
Shapiro, A.D.1
Di Paola, J.2
Cohen, A.3
Pasi, K.J.4
Heisel, M.A.5
Blanchette, V.S.6
|